Feb 29, 2016 by Brian Orelli, PhDWhy Endo International plc Earned a Lower Price TodayAn announcement about subsidiary ASTORA Women's Health in the company's earnings release has investors spooked.
Feb 23, 2016 by Brian Orelli, PhDWhy ZIOPHARM Oncology Inc. Published a Higher Stock Price TodayThe biotech got a scientific paper published, but the devil is in the detail.
Feb 22, 2016 by Brian Orelli, PhDWhy Trevena Inc.'s Shares Broke Through TodayThe company's lead drug candidate received Breakthrough Therapy designation from the FDA.
Feb 19, 2016 by Brian Orelli, PhDMomenta BlockedNovartis, the biotech's partner on Glatopa, is having trouble capturing more of the Copaxone market.
Feb 18, 2016 by Brian Orelli, PhDWhy Momenta Pharmaceuticals, Inc. Earned a Lower Price TodayInvestors might not be happy with the drugmaker's earnings or maybe it's just noise.
Feb 16, 2016 by Brian Orelli, PhDWhy bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped TodayThe trio of biotechs were in investors' good graces today.
Feb 16, 2016 by Brian Orelli, PhDAlnylam Pharmaceuticals, Inc.: Waiting on APOLLOThe biotech offers a pipeline review-filled earnings release, but investors seem to be focused on APOLLO, which won't read out until late next year.
Feb 11, 2016 by Brian Orelli, PhDGenomic Health, Inc. Eyes ProfitabilityWith reimbursement in place, the test maker can get into the black this year.
Feb 10, 2016 by Brian Orelli, PhDWhy NxStage Medical, Inc. Guided Lower TodayDespite a solid increase in revenue, investors in the dialysis company are disappointed with management's lackluster guidance.
Feb 10, 2016 by Brian Orelli, PhDSeattle Genetics, Inc. Grows Sales, Waits for DataWhile Adcetris has had a good run, further sales expansion will require more data showing that it can help patients the drug isn't yet approved to treat.
Feb 9, 2016 by Brian Orelli, PhDWhy Cambrex Corporation Earned a Higher Share Price TodayA solid forecast for the year ahead pumped up the drugmaker.
Feb 8, 2016 by Brian Orelli, PhDThe One Question for Genomic Health, Inc.As the cancer-test maker releases earnings, investors should be focused on profitability.
Feb 8, 2016 by Brian Orelli, PhDQiagen NV Is Prepping for GrowthWith the decline in HPV test sales mostly behind it, the lab-test maker is looking for a stronger 2016 and beyond.
Feb 5, 2016 by Brian Orelli, PhDBaxter International Inc. Rebuilding After Divorce Modest revenue growth expected after the separation, but earnings look nice.
Feb 4, 2016 by Brian Orelli, PhDNovo Nordisk A/S Taps the Growth BrakesThe diabetes specialist expects to see slowing operating growth, but it has a good reason.
Feb 4, 2016 by Brian Orelli, PhDImmunoGen, Inc.'s Earnings Play the Amortization BluesKeep focused on the pipeline because revenue and earnings are going to be bumpy for some time.
Feb 3, 2016 by Brian Orelli, PhDVertex Pharmaceuticals Inc.'s Q4 Revenues Surge on New DrugThe biotech's newest drug, cystic fibrosis treatment Orkambi, is now its top-selling asset.
Feb 2, 2016 by Brian Orelli, PhDBiogen Inc. Slows (But Let's Keep This in Perspective)The pipeline could reaccelerate revenue growth.
Feb 2, 2016 by Brian Orelli, PhDCelldex Therapeutics, Inc. Slips Some MoreAnother down day for the biotech as data approaches.
Feb 1, 2016 by Brian Orelli, PhDbluebird bio Inc. Takes FlightUp 10.6% on no news. Welcome to biotech investing.
![sol_ams[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F197468%2Fsol_ams1.jpg&w=384&op=resize)
